Participated · Series A · Jun 2026

General Intuition builds a single agentic model that learns spatial-temporal reasoning from hundreds of millions of hours of gameplay and associated action labels provided via Medal. The company uses a frame-by-frame generated world model as a training environment and has demonstrated transfer from gameplay to simulation to physical embodiments such as a quadruped robot and drones. It has a handful of customers in gaming, simulation, and robotics and is pursuing a data flywheel strategy that prioritizes partners capable of providing diverse real-world data. General Intuition recently launched Nerve, a jobs marketplace that lets gamers earn money through tasks like data labeling and robot teleoperation. The firm emphasizes ethical limits on use—declining lethal autonomy—and plans to broaden access to its models via a public API by the end of the summer. Financially, the company has raised $454 million in disclosed funding after the latest $320 million round and is directing most new capital toward scaling compute infrastructure.

Participated · Series A · Mar 2024

Tierra Biosciences operates an AI-guided, cell-free platform that produces custom proteins from digital sequences and DNA, enabling customers to order proteins online for pharmaceutical, industrial, and agricultural uses. The platform generates cell-free reagents that are combined with customer sequences and robotic workflows to synthesize proteins and feed data back into a closed-loop AI model. Tierra says its model has produced more than 5,000 proteins to date and that the dataset grows with each run, improving predictive performance. The company currently produces milligram quantities for customers and plans to scale to gram-scale production in the next month or two to support pilot programs. Tierra launched the commercial platform about a year ago, rebranded from Synvitrobio (previously raised $2.6M in 2018) and has secured $7.2M in grants from agencies including ARPA-E, NIH, and DARPA. Management added Michael Nemzek as CEO in 2022 and plans to use new funding to expand customers, build AI data-generation capabilities, and hire a commercial team. Tierra Biosciences is commercializing a cell-free manufacturing platform that strips cellular components to run biochemical reactions in vitro, enabling faster design-build-test cycles and high-throughput data collection. The company emphasizes applications in agricultural and biochemical products while also pursuing biopharmaceutical opportunities. Under CEO Zachary Sun and co-founders Richard Murray and George Church, Tierra positions its platform as a way to run reactions without cell walls by isolating ribosomes and supplying defined substrates and DNA. Tierra is working with Oak Ridge National Laboratory to develop processes to produce vanillin and mevalonate from biomass and says it has partnerships with Global 2000 companies in the works. The startup rebranded from Synvitrobio to emphasize its natural products and biochemical focus and has taken on $2.6 million in new financing. Tierra’s technology is being pitched as broadly applicable across pesticides, flavorings, pharmaceuticals and energy markets. The company has also received support from government and research funders including DARPA, the NIH, the Department of Energy, Cyclotron Road, Lawrence Berkeley National Laboratory, the NSF and the Gates Foundation.

Participated · Series A · Jan 2024

Sion Power develops Licerion® lithium‑metal battery technology intended for electric vehicles. Licerion uses compression in lithium‑metal cells to enhance safety, lifetime, and recharging rates and aims to deliver up to twice the energy of conventional lithium‑ion batteries at up to 500 Wh/kg. The company has demonstrated the technology in large energy capacity cells up to 20Ah and is developing cells to reach 56Ah. With new capital, Sion Power plans to build a fully automated manufacturing line to produce high‑quality large‑format lithium‑metal cells for testing and market development with automotive OEMs and cell manufacturers. The company intends to use the financing to achieve technical and market validation of its technology. Recent board additions include automotive and industry executives and investor representatives to support commercialization efforts. Sion Power is a developer of next-generation rechargeable batteries built around its proprietary Licerion® lithium-metal technology. Licerion® contains roughly twice the energy of a traditional lithium-ion battery in the same size and weight by using a lithium-metal anode and a patented manufacturing process. The company positions the chemistry as an enabling technology to significantly enhance performance for commercial and consumer electric vehicles. Under an agreement with Cummins, Sion Power will run a multi-year program to design and supply large-format lithium-metal cells for integration into Cummins' battery packs and electric powertrains for commercial vehicles. The article states Cummins has made an investment in Sion Power in connection with the agreement, though financial terms are not disclosed. The press release is datelined Tucson, Ariz., and emphasizes Licerion® as a robust, long-lasting rechargeable battery for demanding applications. Sion Power is a developer of next-generation lithium-sulfur (Li-S) rechargeable batteries focused on portable power and electric vehicle applications. The company is based in Tucson, Arizona and was established initially as Moltech Corporation in 1994. Sion has assembled a team of scientists and engineers and holds more than 100 U.S. and international patents on its Li-S technologies. Its lightweight, high-energy cells have enabled an unrefueled flight-endurance world record for unmanned aerial vehicles. Sion is pursuing commercialization of its proprietary Li-S technology for electric and plug-in vehicles and other high-energy applications over the next decade. The company recently received a $50 million equity investment from BASF, expanding their technical collaboration and providing a financial partnership to support development and commercialization.

Participated · Series B · Jul 2021

Antheia is a biosynthesis company focused on transforming pharmaceutical manufacturing through engineered microorganisms that produce complex active pharmaceutical ingredients (APIs). The firm employs its advanced biosynthesis platform to generate critical drug ingredients domestically, reducing reliance on fragile global supply chains. Under an ongoing collaboration with the U.S. government’s BioMaP-Consortium, Antheia will scale commercial production of two essential pharmaceutical compounds in the United States. The company positions its technology as a solution to longstanding vulnerabilities in healthcare supply chains and aims to build a more resilient, on-shore source of medicines for the American market. To date, Antheia has secured $21 million in federal project investment dedicated to this initiative, including a recent $9 million expansion award. These funds will be deployed to increase manufacturing capacity and accelerate the company’s path to large-scale commercialization. No additional operating metrics or revenue figures were disclosed in the article.